Overview
- Researchers published the BioTAK diagnostic score after analyzing more than 3,600 patient samples and validating predefined thresholds in an independent cohort of about 1,800 patients with nearly 90 percent accuracy.
- The score combines five blood biomarkers selected by artificial intelligence with biological sex to separate Takotsubo (broken‑heart) syndrome from acute myocardial infarction before coronary catheterization.
- Key markers include peptidylglycine α‑amidating monooxygenase (PAM), which links to the brain‑heart stress response, and soluble LOX‑1 (sLOX‑1), which is higher in typical heart attacks and lower in Takotsubo patients.
- Study authors, reporting their findings on Monday, August 31, 2026, stress that BioTAK is an adjunctive tool not a replacement for catheterization and that clinical use will require prospective trials and assay standardization.
- If validated in routine practice, the score could spare some mainly postmenopausal women who present after acute stress from unnecessary invasive testing and reshape emergency evaluation by directing imaging and treatment decisions earlier.